ABPI and Bioindustry Association team up to improve biosimilar understanding
The Association of the British Pharmaceutical Industry (ABPI) and the Bioindustry Association (BIA) have teamed up to develop material on biological medicines including biosimilars to improve prescriber and stakeholder understanding and perceptions.
The bodies believe increasing knowledge in this area is important as it is predicted that, by 2016, seven of the top 10 medicines worldwide will be biologics, and since 2006, more than 18 branded biosimilar medicines have been granted marketing authorizations in the EU.
It is expected that the number of biosimilar medicines available in the UK will increase with biosimilars entering a wider range of therapy areas including oncology and diabetes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze